Lupin Ltd Enters into License and Supply Agreement with SteinCares for Biosimilar Ranibizumab in Latin America

Lupin Ltd, a global pharmaceutical leader, has entered into a license and supply agreement with SteinCares, a leading specialty healthcare company in Latin America. The agreement is for the commercialization of Lupin’s biosimilar ranibizumab across Latin America excluding Mexico and Argentina. SteinCares will handle all regulatory filings, registrations and commercialization, while Lupin will be responsible for manufacturing. Ranibizumab is a recombinant humanized lgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). Its indications encompass the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR) and Myopic Choroidal Neovascularization (mCNV). This partnership underscores Lupin’s commitment to providing innovative, high-quality healthcare solutions to patients in LATAM and transforming the landscape of retinal care in Latin America. SteinCares, on the other hand, strengthens its portfolio and further reinforces its position as a biosimilar powerhouse in Latin America.